Company Analysis
Sign in

InflaRx N.V. (IFRX)

Nasdaq: IFRX · Pharmaceutical Preparations · Jena, DE · filing with the SEC since 2017
Full chart Alerts Compare
Grade4.0
◀ Past 4.9● Present 3.5▶ Future 3.8
3 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue€29,331-82.3%
Net income-€45.6M+0.9%
Earnings per share€-0.68+12.8%
Operating cash flow-€35.3M+27.3%
Cash€16.0M-12.8%
Debtn/a
Shareholders’ equity€41.6M-32.3%
Shares, diluted67.3M+14.2%
Return on equity-109.8%
The recordfrom its filings
Filings in 202641
Newest filingNov 6 · 6-K
Annual reportMar 20, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted13
Filer categoryNon-accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in EUR. Nothing here is a forecast.

News

Aug 17, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Aug 14, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
Aug 14, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Aug 12, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton IFRX · research, not advice